Characterization of a clinical Clostridioides difficile isolate with markedly reduced fidaxomicin susceptibility and a V1143D mutation in rpoB.
Schwanbeck J, Riedel T, Laukien F, Schober I, Oehmig I, Zimmermann O, Overmann J, Groß U, Zautner AE, Bohne W. J Antimicrob Chemother. 2019 Jan 1; 74(1):6-10.